Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii sachets plus mesalazine for ulcerative colitis
ChiCTR2600118353Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of Southwest Medical University
- Start
- Feb 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of Salcrozine and saccharomyces boulardii in autoimmune colitis (2 arms), sponsored by Affiliated Hospital of Southwest Medical University. Primary endpoint: Clinical efficacy rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Salcrozinesaccharomyces boulardii
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on ChiCTR2600118353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118353.